Dr. Ulahannan on Immunotherapy in Hepatocellular Carcinoma
July 31st 2018Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses immunotherapy in hepatocellular carcinoma (HCC).
Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer
July 24th 2018Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.
Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer
July 13th 2018Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.